Johnson & Johnson (NYSE:JNJ) Shares Purchased by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 349,105 shares of the company's stock after purchasing an additional 5,251 shares during the period. Johnson & Johnson makes up 1.0% of Kornitzer Capital Management Inc. KS's investment portfolio, making the stock its 22nd biggest holding. Kornitzer Capital Management Inc. KS's holdings in Johnson & Johnson were worth $50,488,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Mraz Amerine & Associates Inc. boosted its holdings in Johnson & Johnson by 38.9% during the fourth quarter. Mraz Amerine & Associates Inc. now owns 24,118 shares of the company's stock valued at $3,488,000 after acquiring an additional 6,760 shares during the period. Venturi Wealth Management LLC raised its position in shares of Johnson & Johnson by 61.7% during the fourth quarter. Venturi Wealth Management LLC now owns 19,662 shares of the company's stock valued at $2,843,000 after buying an additional 7,502 shares during the last quarter. Citizens & Northern Corp raised its position in Johnson & Johnson by 14.7% in the fourth quarter. Citizens & Northern Corp now owns 2,555 shares of the company's stock worth $370,000 after purchasing an additional 327 shares in the last quarter. CIBC Asset Management Inc raised its position in Johnson & Johnson by 14.6% in the fourth quarter. CIBC Asset Management Inc now owns 727,111 shares of the company's stock worth $105,139,000 after purchasing an additional 92,389 shares in the last quarter. Finally, KLCM Advisors Inc. raised its position in Johnson & Johnson by 2.0% in the fourth quarter. KLCM Advisors Inc. now owns 7,186 shares of the company's stock worth $1,039,000 after purchasing an additional 140 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on JNJ shares. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Stifel Nicolaus decreased their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research note on Thursday, January 23rd. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective on the stock. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Finally, Bank of America decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $170.67.

Johnson & Johnson Stock Up 1.7 %

Shares of NYSE:JNJ traded up $2.67 during midday trading on Friday, reaching $162.35. 12,540,171 shares of the company were exchanged, compared to its average volume of 9,073,381. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The stock has a fifty day simple moving average of $148.61 and a two-hundred day simple moving average of $155.89. The firm has a market cap of $390.87 billion, a PE ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.29 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is presently 74.59%.

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.